This Little Pig-Free Product Goes To Market? Alnara's High Hopes For A PERT
This article was originally published in The Pink Sheet Daily
Executive Summary
Alnara claims its latest trial shows real-world effectiveness of liprotamase, formerly called Trizytek, and plans early 2010 NDA.
You may also be interested in...
Sollpura's Future After No Vote From Panel Might Include More Trials, Adult Indication
FDA's Gastrointestinal Drugs Advisory Committee says in lopsided votes that Lilly's exocrine pancreatic insufficiency drug candidate Sollpura (liprotamase) lacks proof of efficacy.
Sollpura's Future After No Vote From Panel Might Include More Trials, Adult Indication
FDA's Gastrointestinal Drugs Advisory Committee says in lopsided votes that Lilly's exocrine pancreatic insufficiency drug candidate Sollpura (liprotamase) lacks proof of efficacy.
Lilly's Solpura Advisory Committee Could Hinge On Manufacturing Issues
Alnara, a Lilly subsidiary, says that its exocrine pancreatic insufficiency treatment is supported by two adequate and well-controlled trials, but FDA says that the product has changed so much that only one of them is relevant - and that one doesn't show strong enough efficacy.